It showed that ADT for polymetastases could be delayed by 8 months IF one is willing to accept only 80% confidence in the statistics in this pilot study (and IF one is willing to accept that ADT can be delayed until there are 4 simultaneous metastases). At the conventional 95% confidence, there was no statistically significant difference. But this begs the question of whether ADT should EVER be delayed when there are known metastases. When I mentioned that to Dr. Ost, he was appalled that his study would be abused for that purpose. He wrote, "MDT does not replace ADT and our results should not be interpreted in that way."
Importantly, this study does NOT address whether there is a survival advantage or disadvantage to metastasis-directed therapy, which is what we really want to know. We await other clinical trial to answer that question. What we know for a fact (from 4 major randomized trials) is that, among newly diagnosed patients, aggressive systemic therapy, as early as possible after metastases are discovered, provides significant survival advantage.
Here's an article about
it:
/pcnrv.blogspot.com/2017/12/metastasis-directed-therapy-for.html